The public consultation of the draft methodological guideline “Practical considerations when critically assessing economic evaluations” is OPEN (deadline Oct. 11, 2019)
We are pleased to announce that, as of today, the draft methodological guideline “Practical considerations when critically assessing economic evaluations”, produced within WP6 B2, has entered the public consultation phase. This consultation will be open until 11th October, 2019. Objective of the methodological guideline EUnetHTA´s methodological guidelines are targeted to the needs of health […]
Open Call for Patient Input for a new Joint Assessment on a medicinal product for severe Gram-negative (bacterial) infections.
Patient group input requested for a new Joint Assessment on a medicinal product for severe Gram-negative (bacterial) infections. EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or […]
OTCA22 – “Clinical utility of Point-of-care Tests (POCT) D-Dimer and Troponin” project plan and comments from external experts are now available.
EUnetHTA is pleased to announce that the project plan and and comments from external experts for the Other Technologies Collaborative Assessment OTCA22 “Clinical utility of Point-of-care Tests (POCT) D-Dimer and Troponin” are now available for access. The final assessment report will be published on 29th November, 2019. Please access the project plan and external expert […]
The minutes from the EUnetHTA-EFPIA Technical Meeting, held on 11th December 2018 at the Haute Autorité de Santé in Paris, are now available for access. Participants included attendees from both EFPIA and EUnetHTA, as well as the EMA and DG SANTE. Topics presented and discussed included: Governance changes in EUnetHTA; Various developments and experiences from […]
PTJA11 addresses ‘cefiderocol the for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options’, submitted by Shionogi BV. We are delighted that AIFA and NOMA are authoring this assessment. We will be issuing an Open Call for Patient Input in due course.
The public consultation of the revision of the methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness” is OPEN (deadline 27th September, 2019)
We are pleased to announce that, as of today, a revised version of the methodological guideline “Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness”, produced within WP6 B2, has entered the public consultation phase. This consultation will be open until 27th September, 2019. PLEASE NOTE: This was initially 13th […]
PTJA07 Pharmaceutical Joint Assessment Now Available – ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active UC who have had an inadequate response with, lost response to or were intolerant to […]
The EUnetHTA Executive Board recently adopted the following Understanding of EUnetHTA HTA. This text is the result of several months of consultation with the project’s board. The EUnetHTA Executive Board agreed that HTA in the context of EUnetHTA activities is understood to be composed of the following elements: Assessments should inform decision-making. Assessments are not decision-making processes themselves. Information should […]
EUnetHTA started an “Error reporting and correction” procedure on 04/05/2020. The reported error was not classified as an error by EUnetHTA and the Assessment Team, therefore no changes to the assessment report were needed. The comments received including the answers from the authoring team are published for transparency reasons. See here. We are pleased to […]
EUnetHTA is pleased to announce the publication of the second iteration of the EPL. As part of the overarching Topic Identitication, Selection and Prioritisation (TISP) task group, the EPL is a valuable strategic tool for companies to identify the significant interest of national HTA bodies in relation to specific listed compounds. EUnetHTA seeks to increase […]